Trial Profile
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
- Indications Multiple organ failure; Sepsis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Enlivex Therapeutics
- 11 Apr 2024 According to an Enlivex Therapeutics media release, Company expects to release further details about the study in a forthcoming presentation.
- 11 Apr 2024 Results presented in the Enlivex Therapeutics Media Release
- 11 Apr 2024 According to an Enlivex Therapeutics media release, the company will host a conference call and webcast on April 12, 2024, at 8:30am ET (15:30 IL time) to discuss topline results from its Phase II trial of Allocetra in patients with sepsis